Literature DB >> 29931168

Adult Glioma Incidence and Survival by Race or Ethnicity in the United States From 2000 to 2014.

Quinn T Ostrom1,2, David J Cote3,4,5, Mustafa Ascha6, Carol Kruchko1, Jill S Barnholtz-Sloan1,7.   

Abstract

Importance: Glioma is the most commonly occurring malignant brain tumor in the United States, and its incidence varies by age, sex, and race or ethnicity. Survival after brain tumor diagnosis has been shown to vary by these factors. Objective: To quantify the differences in incidence and survival rates of glioma in adults by race or ethnicity. Design, Setting, and Participants: This population-based study obtained incidence data from the Central Brain Tumor Registry of the United States and survival data from Surveillance, Epidemiology, and End Results registries, covering the period January 1, 2000, to December 31, 2014. Average annual age-adjusted incidence rates with 95% CIs were generated by glioma histologic groups, race, Hispanic ethnicity, sex, and age groups. One-year and 5-year relative survival rates were generated by glioma histologic groups, race, Hispanic ethnicity, and insurance status. The analysis included 244 808 patients with glioma diagnosed in adults aged 18 years or older. Data were collected from January 1, 2000, to December 31, 2014. Data analysis took place from December 11, 2017, to January 31, 2018.
Results: Overall, 244 808 patients with glioma were analyzed. Of these, 150 631 (61.5%) were glioblastomas, 46 002 (18.8%) were non-glioblastoma astrocytomas, 26 068 (10.7%) were oligodendroglial tumors, 8816 (3.6%) were ependymomas, and 13 291 (5.4%) were other glioma diagnoses in adults. The data set included 137 733 males (56.3%) and 107 075 (43.7%) females. There were 204 580 non-Hispanic whites (83.6%), 17 321 Hispanic whites (7.08%), 14 566 blacks (6.0%), 1070 American Indians or Alaska Natives (0.4%), and 5947 Asians or Pacific Islanders (2.4%). Incidences of glioblastoma, non-glioblastoma astrocytoma, and oligodendroglial tumors were higher among non-Hispanic whites than among Hispanic whites (30% lower overall), blacks (52% lower overall), American Indians or Alaska Natives (58% lower overall), or Asians or Pacific Islanders (52% lower overall). Most tumors were more common in males than in females across all race or ethnicity groups, with the great difference in glioblastoma where the incidence was 60% higher overall in males. Most tumors (193 329 [79.9%]) occurred in those aged 45 years or older, with differences in incidence by race or ethnicity appearing in all age groups. Survival after diagnosis of glioma of different subtypes was generally comparable among Hispanic whites, blacks, and Asians or Pacific Islanders but was lower among non-Hispanic whites for many tumor types, including glioblastoma, irrespective of treatment type. Conclusions and Relevance: Incidence of glioma and 1-year and 5-year survival rates after diagnosis vary significantly by race or ethnicity, with non-Hispanic whites having higher incidence and lower survival rates compared with individuals of other racial or ethnic groups. These findings can inform future discovery of risk factors and reveal unaddressed health disparities.

Entities:  

Mesh:

Year:  2018        PMID: 29931168      PMCID: PMC6143018          DOI: 10.1001/jamaoncol.2018.1789

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN: 2374-2437            Impact factor:   31.777


  35 in total

1.  Racial/ethnic differences in survival among elderly patients with a primary glioblastoma.

Authors:  Jill S Barnholtz-Sloan; John L Maldonado; Vonetta L Williams; William T Curry; Elizabeth A Rodkey; Frederick G Barker; Andrew E Sloan
Journal:  J Neurooncol       Date:  2007-05-26       Impact factor: 4.130

2.  Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma.

Authors:  Felix Sahm; David Reuss; Christian Koelsche; David Capper; Jens Schittenhelm; Stephanie Heim; David T W Jones; Stefan M Pfister; Christel Herold-Mende; Wolfgang Wick; Wolf Mueller; Christian Hartmann; Werner Paulus; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2014-08-21       Impact factor: 17.088

3.  Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying).

Authors:  Quinn T Ostrom; Haley Gittleman; Carol Kruchko; David N Louis; Daniel J Brat; Mark R Gilbert; Valentina I Petkov; Jill S Barnholtz-Sloan
Journal:  J Neurooncol       Date:  2016-07-14       Impact factor: 4.130

4.  The Patient Protection and Affordable Care Act dependent coverage expansion: Disparities in impact among young adult oncology patients.

Authors:  Elysia M Alvarez; Theresa H Keegan; Emily E Johnston; Robert Haile; Lee Sanders; Paul H Wise; Olga Saynina; Lisa J Chamberlain
Journal:  Cancer       Date:  2017-09-22       Impact factor: 6.860

Review 5.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

6.  How generalizable are the SEER registries to the cancer populations of the USA?

Authors:  Tzy-Mey Kuo; Lee R Mobley
Journal:  Cancer Causes Control       Date:  2016-07-21       Impact factor: 2.506

7.  Surgical management of incidentally discovered diffusely infiltrating low-grade glioma.

Authors:  Michael Opoku-Darko; Stefan T Lang; James Artindale; J Gregory Cairncross; Robert J Sevick; John J P Kelly
Journal:  J Neurosurg       Date:  2017-10-06       Impact factor: 5.115

Review 8.  Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review.

Authors:  Melissa Z Braganza; Cari M Kitahara; Amy Berrington de González; Peter D Inskip; Kimberly J Johnson; Preetha Rajaraman
Journal:  Neuro Oncol       Date:  2012-09-05       Impact factor: 12.300

9.  Surveillance for Health Care Access and Health Services Use, Adults Aged 18-64 Years - Behavioral Risk Factor Surveillance System, United States, 2014.

Authors:  Catherine A Okoro; Guixiang Zhao; Jared B Fox; Paul I Eke; Kurt J Greenlund; Machell Town
Journal:  MMWR Surveill Summ       Date:  2017-02-24

10.  Area-based socioeconomic position and adult glioma: a hierarchical analysis of surveillance epidemiology and end results data.

Authors:  Jesse J Plascak; James L Fisher
Journal:  PLoS One       Date:  2013-04-09       Impact factor: 3.240

View more
  128 in total

1.  Glioma risk associated with extent of estimated European genetic ancestry in African Americans and Hispanics.

Authors:  Quinn T Ostrom; Kathleen M Egan; L Burt Nabors; Travis Gerke; Reid C Thompson; Jeffrey J Olson; Renato LaRocca; Sajeel Chowdhary; Jeanette E Eckel-Passow; Georgina Armstrong; John K Wiencke; Jonine L Bernstein; Elizabeth B Claus; Dora Il'yasova; Christoffer Johansen; Daniel H Lachance; Rose K Lai; Ryan T Merrell; Sara H Olson; Siegal Sadetzki; Joellen M Schildkraut; Sanjay Shete; Richard S Houlston; Robert B Jenkins; Margaret R Wrensch; Beatrice Melin; Christopher I Amos; Jason T Huse; Jill S Barnholtz-Sloan; Melissa L Bondy
Journal:  Int J Cancer       Date:  2019-04-22       Impact factor: 7.396

Review 2.  Genetic and molecular epidemiology of adult diffuse glioma.

Authors:  Annette M Molinaro; Jennie W Taylor; John K Wiencke; Margaret R Wrensch
Journal:  Nat Rev Neurol       Date:  2019-06-21       Impact factor: 42.937

3.  European genetic ancestry associated with risk of childhood ependymoma.

Authors:  Chenan Zhang; Quinn T Ostrom; Helen M Hansen; Julio Gonzalez-Maya; Donglei Hu; Elad Ziv; Libby Morimoto; Adam J de Smith; Ivo S Muskens; Cassie N Kline; Zalman Vaksman; Hakon Hakonarson; Sharon J Diskin; Carol Kruchko; Jill S Barnholtz-Sloan; Vijay Ramaswamy; Francis Ali-Osman; Melissa L Bondy; Michael D Taylor; Catherine Metayer; Joseph L Wiemels; Kyle M Walsh
Journal:  Neuro Oncol       Date:  2020-11-26       Impact factor: 12.300

Review 4.  Barriers to accrual and enrollment in brain tumor trials.

Authors:  Eudocia Q Lee; Ugonma N Chukwueke; Shawn L Hervey-Jumper; John F de Groot; Jose Pablo Leone; Terri S Armstrong; Susan M Chang; David Arons; Kathy Oliver; Kay Verble; Al Musella; Nicole Willmarth; Brian M Alexander; Amanda Bates; Lisa Doherty; Evanthia Galanis; Sarah Gaffey; Thomas Halkin; Bret E Friday; Maryam Fouladi; Nancy U Lin; David Macdonald; Minesh P Mehta; Marta Penas-Prado; Michael A Vogelbaum; Solmaz Sahebjam; David Sandak; Martin van den Bent; Michael Weller; David A Reardon; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2019-09-06       Impact factor: 12.300

5.  Glioma incidence and survival variations by county-level socioeconomic measures.

Authors:  David J Cote; Quinn T Ostrom; Haley Gittleman; Kelsey R Duncan; Travis S CreveCoeur; Carol Kruchko; Timothy R Smith; Meir J Stampfer; Jill S Barnholtz-Sloan
Journal:  Cancer       Date:  2019-06-17       Impact factor: 6.860

Review 6.  Response Assessment in Neuro-Oncology Criteria for Gliomas: Practical Approach Using Conventional and Advanced Techniques.

Authors:  D J Leao; P G Craig; L F Godoy; C C Leite; B Policeni
Journal:  AJNR Am J Neuroradiol       Date:  2019-12-19       Impact factor: 3.825

7.  The effects of ephrinB2 signaling on proliferation and invasion in glioblastoma multiforme.

Authors:  Shilpa Bhatia; Sanjana Bukkapatnam; Benjamin Van Court; Andy Phan; Ayman Oweida; Jacob Gadwa; Adam C Mueller; Miles Piper; Laurel Darragh; Diemmy Nguyen; Ahmed Gilani; Michael Knitz; Thomas Bickett; Adam Green; Sujatha Venkataraman; Rajeev Vibhakar; Diana Cittelly; Sana D Karam
Journal:  Mol Carcinog       Date:  2020-06-22       Impact factor: 4.784

8.  Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells.

Authors:  David M Peereboom; Tyler J Alban; Matthew M Grabowski; Alvaro G Alvarado; Balint Otvos; Defne Bayik; Gustavo Roversi; Mary McGraw; Pengjing Huang; Alireza M Mohammadi; Harley I Kornblum; Tomas Radivoyevitch; Manmeet S Ahluwalia; Michael A Vogelbaum; Justin D Lathia
Journal:  JCI Insight       Date:  2019-11-14

9.  Race influences survival in glioblastoma patients with KPS ≥ 80 and associates with genetic markers of retinoic acid metabolism.

Authors:  Meijing Wu; Jason Miska; Ting Xiao; Peng Zhang; J Robert Kane; Irina V Balyasnikova; James P Chandler; Craig M Horbinski; Maciej S Lesniak
Journal:  J Neurooncol       Date:  2019-01-31       Impact factor: 4.130

10.  Static 18F-FET PET and DSC-PWI based on hybrid PET/MR for the prediction of gliomas defined by IDH and 1p/19q status.

Authors:  Shuangshuang Song; Leiming Wang; Hongwei Yang; Yongzhi Shan; Ye Cheng; Lixin Xu; Chengyan Dong; Guoguang Zhao; Jie Lu
Journal:  Eur Radiol       Date:  2020-11-19       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.